Pharmacodynamics of antimicrobials: Treatment optimisation

Expert Opinion on Drug Metabolism and Toxicology

Volumn 1, Issue 3, 2005, Pages 351-361

  Gillespie, Effie L ^a   Kuti, Joseph L ^b   Nicolau, David P ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

antibiotics; antimicrobial therapy; pharmacodynamics

Indexed keywords

ANTIINFECTIVE AGENT; LACTAM;

ANIMAL; BACTERIAL INFECTION; HUMAN; MICROBIOLOGY; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; HUMANS; LACTAMS;

EID: 33747831883     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.1.3.351     Document Type: Review

References (74)

1. JONES RN, PFALLER MA: Bacterial resistance: a worldwide problem. Diagn. Microbiol. Infect. Dis. (1998) 31:379-388. (Pubitemid 28255140)
2. KOLLEF MH, SHERMAN G, WARD S, et al.: Inadequate antimicrobial treatments of infections: a risk factor for hospital mortality among critically ill patients. Chest (1999) 115:462-474. (Pubitemid 29083057)
3. KOLLEF MH: Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis. (2000) 31:S131-S138. (Pubitemid 32291120)
4. IBRAHIM EH, SHERMAN G, WARD S et al.: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest (2000) 118:146-155. (Pubitemid 30485502)
5. KANG CI, KIM SH, KIM HB, et al.: Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. (2003) 37:745-751.
6. TROUILLET JL, CHASTRE J, VUAGNAT A, et al.: Ventilator-associated pneumonia caused by potentially drug resistant bacteria. Am. J. Respir. Crit. Care Med. (1998) 157:531-539. (Pubitemid 28090546)
7. DRUSANO GL: Prevention of resistance: a goal for dose selection of antimicrobial agents. Clin. Infect. Dis. (2003) 36(Suppl 1):S42-S50. (Pubitemid 36140468)
8. NIGHTINGALE CH, MURAKAWA T: Microbiology and pharmacokinetics. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale, Murakawa, Ambrose (Eds), Marcel Dekker, Inc., New York, NY, USA (2002):23-39.
9. DRUSANO GL: Antimicrobial pharmacodynamics: critical interactions of ?bug and drug?. Nature Reviews Microbiology (2004) 2:289-300. (Pubitemid 39490099)
10. CRAIG WA: Pharmacodynamics of antimicrobials: general concepts and applications. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice.. Nightingale, Murakawa, Ambrose (Eds), Marcel Dekker, Inc., New York, NY, USA (2002):1-22.
11. NICOLAU DP: Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J. Infect. Chemother. (2003) 9:292-296. (Pubitemid 38031323)
12. GILLESPIE EL, KUTI JL, NICOLAU DP: When ?S? does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection. Conn. Med. (2005) 69:203-210. (Pubitemid 40586359)
13. CRAIG WA: Pharmacokinetic/ pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. (1998) 26:1-12. (Pubitemid 28068148)
14. LI J, TURNIDGE J, MILNE R, et al.: In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. (2001) 45:781-785. (Pubitemid 32182025)
15. MOORE RD, SMITH CR, LIETMAN PS: Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am. J. Med. (1984) 77:657-662. (Pubitemid 14047595)
16. MOORE RD, SMITH CR, LIETMAN PS: The association of aminoglycoside plasma levels with mortality in patients with Gram-negative bacteremia. J. Infect. Dis. (1984) 149:443-448. (Pubitemid 14138249)
17. MOORE RD, LIETMAN PS, SMITH CR: Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. (1987) 155:93-99. (Pubitemid 17225088)
18. PRESTON SL, DRUSANO GL, BERMAN AL, et al.: Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA (1998) 279:125-129. (Pubitemid 28068302)
19. FREEMAN CD, NICOLAU DP, BELLIVEAU PP, et al.: Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J. Antimicrob. Chemother. (1997) 39:677-686. (Pubitemid 27296406)
20. LACY MK, LU W, XU X, et al.: Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. (1999) 43:672-677. (Pubitemid 29109538)
21. WRIGHT DH, BROWN GH, PETERSON ML, et al.: Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. (2000) 46:669-683.
22. FORREST A, NIX DE, BALLOW CH et al.: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. (1993) 37:1073-1081. (Pubitemid 23141323)
23. AMBROSE PG, GRASELA DM, GRASELA TH, et al.: Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with communityacquired respiratory tract infections. Antimicrob. Agents Chemother. (2001) 45:2793-2797. (Pubitemid 32906673)
24. DRUSANO GL, PRESTON SL, FOWLER C, et al.: Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis. (2004) 189:1590-1597. (Pubitemid 38648286)
25. BRUEGGEMANN AB, COFFMAN SL, RHOMBERG P, et al.: Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. (2002) 46:680-688. (Pubitemid 34157651)
26. LIM S, BAST D, MCGEER A, et al.: Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg. Infect. Dis. (2003) 9:833-837. (Pubitemid 36801584)
27. FLOREA NR, TESSIER PR, ZHANG C et al.: Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2004) 48:1215-1221. (Pubitemid 38405475)
28. ALLEN GP, KAATZ GW, RYBAK MJ: Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. (2003) 47:2606-2614. (Pubitemid 36919466)
29. JUMBE N, LOUIE A, LEARY R, et al.: Application of a mathematical model to prevent in vivo amplification of antibioticresistant bacterial populations during therapy. J. Clin. Invest. (2003) 112:275-285. (Pubitemid 38056363)
30. TAM VH, LOUIE A, DEZIEL MR, et al.: Bacterial-population responses to drugselective pressure: examination of garenoxacin?s effect on Pseudomonas aeruginosa. J. Infect. Dis. (2005) 192:420-428. (Pubitemid 41023120)
31. DERYKE CA, LEE SY, KUTI JL, et al.: Optimizing dosing strategies utilizing pharmacodynamic principles: impact on the development of resistance. Drugs (in press).
32. TURNIDGE JD: The pharmacodynamics of β-lactams. Clin. Infect. Dis. (1998) 27:10-22.
33. MAGLIO D, ONG C, BANEVICIUS MA, et al.: Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-betalactamase- producing Escherichia coli at various inocula. Antimicrob. Agents Chemother. (2004) 48:1941-1947. (Pubitemid 38691580)
34. MATTOES HM, KUTI JL, DRUSANO GL, et al.: Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin. Ther. (2004) 26:1187-1198. (Pubitemid 39445343)
35. SCHENTAG JJ, SMITH IL, SWANSON DF, et al.: Role of dual individualization with cefmenoxime. Am. J. Med. (1984) 77:43-50.
36. DAGAN R, KLUGMAN KP, CRAIG WA et al.: Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. (2001) 47:129-140. (Pubitemid 32149516)
37. TAM VH, MCKINNON PS, AKINS RL et al.: Pharmacodynamics of cefepime in patients with Gram-negative infections. J. Antimicrob. Chemother. (2002) 50:425-428.
38. LODISE TP, PRESTON S, BHARGAVA V et al.: Pharmacodynamics of an 800-mg dose of telitromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn. Microbiol. Infect. Dis. (2005) 52:45-52. (Pubitemid 40692739)
39. KUTI JL, NIGHTINGALE CH, NICOLAU DP: Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram (OPTAMA) program-North America. Antimicrob. Agents Chemother. (2004) 48:2464-2470. (Pubitemid 38823411)
40. KIFFER CRV, MENDES C, KUTI JL et al.: Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. Diagn. Microbiol. Infect. Dis. (2004) 49:109-116. (Pubitemid 38746740)
41. MOUTON JW, DUDLEY MN, CARS O et al.: Standardization of pharmacokinetic/ pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. (2005) 55:601-607. (Pubitemid 40691835)
42. JONES RN, RUBINO CM, BHAVNANI SM, et al.: Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob. Agents Chemother. (2003) 47:292-296. (Pubitemid 36070377)
43. AMBROSE PG, BHAVNANI SM, JONES RN: Pharmacokineticspharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob. Agents Chemother. (2003) 47:1643-1646. (Pubitemid 36548549)
44. LIVERMORE DM: The need for new antibiotics. Clinical Microbiol Infect (2004) 10(Suppl. 4):1-9.
45. CRAIG WA: Post-antibiotic effects in experimental infection models: relationship to in vitro phenomena and to treatment of infections in man. J. Antimicrob. Chemother. (1993) 31(Suppl. D):149-158. (Pubitemid 23193761)
46. MALLER R, AHRNE H, EILARD T, et al.: Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. J. Antimicrob. Chemother. (1991) 27:121S-128S.
47. PRINS JM, BULLER HR, KUIJPER EJ et al.: Once versus thrice daily gentamicin in patients with serious infections. Lancet (1993) 341:335-339. (Pubitemid 23039700)
48. INTERNATIONAL ANTIMICROBIAL THERAPY COOPERATIVE GROUP OF THE EORTC: Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann. Intern. Med. (1993) 119:584-593.
49. MARIK PE, LIPMAN J, KOBILSKI S et al.: A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and pediatric patients. J. Antimicrob. Chemother. (1991) 28:753-764.
50. GILBERT DN, LEE BL, DWORKIN RJ et al.: A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate. Am. J. Med. (1998) 105:182-191. (Pubitemid 28443206)
51. KASHUBA ADM, BERTINO JS, NAFZIGER AN: Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by Gram-negative organisms. Antimicrob. Agents Chemother. (1998) 42:1842-1844. (Pubitemid 28311589)
52. WALLACE AW, JONES M, BERTINO JS: Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacother. (2002) 22:1077-1083. (Pubitemid 34969059)
53. NICOLAU DP, FREEMAN CD, BELLIVEAU PP, et al.: Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. (1995) 39:650-655.
54. ANAIZI N: Once daily dosing of aminoglycosides: a consensus document. Int. J. Clin. Pharmacol. Ther. (1997) 35:223-226. (Pubitemid 27268168)
55. GILBERT DN, MOELLERING RC JR, SANDE MA: The Sanford guide to antimicrobial therapy 2001, 31st ed. Antimicrobial Therapy, Inc., Hyde Park, VT, USA (2001).
56. MYERS DR, DEFEHR J, BENNET WM et al.: Gentamicin binding to serum and plasma proteins. Clin. Pharmacol. Ther. (1978) 23:356-360. (Pubitemid 8302194)
57. KOTAPATI SL, KUTI JL, NIGHTINGALE CH, et al.: Role of pharmacodynamics in designing dosage regimens for β-lactams. Conn. Med. (2003) 67:265-268. (Pubitemid 36622559)
58. KUTI JL, MAGLIO D, NIGHTINGALE CH, et al.: Economic benefit of a pharmacodynamic influenced meropenem dosing strategy. Am. J. Health- Syst. Pharm. (2003) 60:565-568. (Pubitemid 36752884)
59. NICOLAU DP, AMBROSE PG: Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am. J. Med. (2001) 111:13S-18S.
60. BODEY GP, KETCHEL SJ, RODRIGUEZ VA: A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes of cancer patients. Am. J. Med. (1979) 67:608-616. (Pubitemid 10249299)
61. MACGOWEN AP, BOWKER KE: Continuous infusion of β-lactam antibiotics. Clin. Pharmacokinetics (1998) 35:391-402.
62. GRANT EM, KUTI JL, NICOLAU DP et al.: Clinical efficacy and pharmacoeconomics of a continuous infusion piperacillin/tazobactam program in a large community teaching hospital. Pharmacother. (2002) 22:471-483. (Pubitemid 34270031)
63. THALHAMMER F, TRAUNMULLER F, EL MENYAWI I, et al.: Continuous infusion versus intermittent administration of meropenem in critically ill patients. J. Antimicrob. Chemother. (1999) 43:523-527. (Pubitemid 29182302)
64. KUTI JL, NIGHTINGALE CH, KNAUFT R, et al.: Pharmacokinetics and stability of continuously infused meropenem in adults with cystic fibrosis. Clin. Ther. (2004) 26:493-501. (Pubitemid 38586450)
65. NICOLAU DP, MCNABB JC, LACY MK et al.: Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int. J. Antimicrob. Agents (2001) 17:497-504. (Pubitemid 32492970)
66. BOSELLI E, BREILH D, DUFLO F, et al.: Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit. Care Med. (2003) 31:2102-2106. (Pubitemid 37011688)
67. KRUEGER WA, BULITTA J, KINZIG-SCHIPPERS M, et al.: Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob. Agents Chemother. (2005) 49:1881-1889. (Pubitemid 40631603)
68. DANDEKAR PK, MAGLIO D, SUTHERLAND CA, et al.: Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacother. (2003) 23:988-991. (Pubitemid 36903999)
69. JARURATANASIRIKUL S, SRIWIRIYAJAN S, PUNYO J: Comparison of the pharmacodynamics of meropenem in patients with ventilatorassociated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob. Agents Chemother. (2005) 49:1337-1339. (Pubitemid 40463358)
70. KUTI JL, MOSS KM, NICOLAU DP et al.: Empiric treatment of multidrugresistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. Pharmacother. (2004) 24:1641-1645. (Pubitemid 39426358)
71. CAPITANO B, NICOLAU DP, POTOSKI BA, et al.: Meropenem administered as a prolonged infusion to treat serious Gram-negative central nervous system infections. Pharmacother. (2004) 24:803-807. (Pubitemid 38747867)
72. LODISE TP, LOMAESTRO BM, DRUSANO GL: Evaluation of the clinical and economic implications of an extended infusion dosing strategy of piperacillin/ tazobactam for Pseudomonas aeruginosa infections [abstract O-1617]. In: Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society of Microbiology, Washington, DC, USA (2004):446.
73. http://www.idsociety.org Bad bugs, no drugs- as antibiotic discovery stagnates?a public health crisis brewsexecutive summary: IDSA (2004).
74. http://internalmed.wustl.edu/divisions/ house-staff/aminoglycosides.html Infrequent aminoglycoside dosing, from Barnes-Jewish Hospital at Washington University Medical Center.